Publikationen, an denen er mitarbeitet TAMARA FERNANDEZ VALLE (13)

2024

  1. Implication of nutrition in severity of symptoms and treatments in quality of life in Parkinson’s disease: a systematic review

    Frontiers in Nutrition, Vol. 11

  2. Plasma Neurofilament Light Chain: A Potential Biomarker for Neurological Dysfunction in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome

    Biomedicines, Vol. 12, Núm. 7

  3. Understanding the olfactory role in post-COVID cognitive and neuropsychiatric manifestations

    Frontiers in Psychology, Vol. 15

2023

  1. Clinical phenotype of postural orthostatic tachycardia associated with anti-adrenergic receptor antibodies

    Gaceta médica de Bilbao: Revista oficial de la Academia de Ciencias Médicas de Bilbao. Información para profesionales sanitarios, Vol. 120, Núm. 2, pp. 66-73

  2. Dysautonomia and small fiber neuropathy in post-COVID condition and Chronic Fatigue Syndrome

    Journal of Translational Medicine, Vol. 21, Núm. 1

  3. Retinal thickness as a biomarker of cognitive impairment in manifest Huntington’s disease

    Journal of Neurology, Vol. 270, Núm. 8, pp. 3821-3829

2022

  1. Characterization of molecular biomarkers in cerebrospinal fluid and serum of E46K-SNCA mutation carriers

    Parkinsonism and Related Disorders, Vol. 96, pp. 29-35

  2. Impact of Visual Impairment on Vision-Related Quality of Life in Parkinson's Disease

    Journal of Parkinson's Disease, Vol. 12, Núm. 5, pp. 1633-1643

2021

  1. Quantitative analysis of dysautonomia in patients with autonomic dysreflexia

    Journal of Neurology, Vol. 268, Núm. 8, pp. 2985-2994

  2. Retinal Thickness Predicts the Risk of Cognitive Decline in Parkinson Disease

    Annals of Neurology, Vol. 89, Núm. 1, pp. 165-176

2019

  1. New therapeutic approaches to target alpha-synuclein in Parkinson's disease: The role of immunotherapy

    International Review of Neurobiology (Academic Press Inc.), pp. 281-295

2018

  1. Anti-IgLON5 Disease Responsive to Immunotherapy: A Case Report with an Abnormal MRI

    Movement Disorders Clinical Practice, Vol. 5, Núm. 6, pp. 653-656

  2. Clinical treatment of chronic and episodic migraine with onabotulinumtoxinA in a real-world setting

    Drugs and Therapy Perspectives, Vol. 34, Núm. 7, pp. 335-343